Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy

Stephanie Chen1 BioPharmaceuticals Medical, Respiratory & Immunology, AstraZeneca, Gaithersburg, MD, USAView further author information

Marc Miravitlles2 Pneumology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain

https://orcid.org/0000-0002-9850-9520 View further author information

Chin Kook Rhee3 College of Medicine, Seoul St Mary’s Hospital, the Catholic University of Korea, Seoul, South KoreaView further author information

Ian D Pavord4 Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK

https://orcid.org/0000-0002-4288-5973 View further author information

Rupert Jones5 Faculty of Health, University of Plymouth, Plymouth, UKView further author information

Victoria Carter6 Observational and Pragmatic Research Institute, Singapore, SingaporeView further author information

Benjamin Emmanuel1 BioPharmaceuticals Medical, Respiratory & Immunology, AstraZeneca, Gaithersburg, MD, USAView further author information

Marianna Alacqua7 BioPharmaceuticals Medical, Respiratory & Immunology, AstraZeneca, Cambridge, UKView further author information

David B Price6 Observational and Pragmatic Research Institute, Singapore, Singapore;8 Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UKCorrespondence[email protected]

https://orcid.org/0000-0002-9728-9992 View further author information

show all

Figures & data

Figure 1 Study design.

Abbreviations: COPD, chronic obstructive pulmonary disease; HCRU, health care resource utilization.

Table 1 Characteristics of Patient Cohorts and Subgroups in the Year Prior to the Index Date

Download CSV Display Table

Table 2 HCRU Events and Mortality During the Outcome Year

Download CSV Display Table

Figure 2 Exacerbations in the outcome year according to years with at least 1 exacerbation over 10 years prior to the index date. (A) Percentage of patients experiencing exacerbations in the outcome year in the maintenance-treated COPD cohort. (B) Percentage of patients experiencing exacerbations in the outcome year in the frequently exacerbating cohort.

Abbreviation: COPD, chronic obstructive pulmonary disease.

Figure 3 Exacerbations and hospitalizations in the outcome year according to exacerbations and hospitalizations in the year prior to the index date. (A) Percentage of patients experiencing exacerbations and hospitalizations in the outcome year in the maintenance-treated COPD cohort. (B) Percentage of patients experiencing exacerbations and hospitalizations in the outcome year in the frequently exacerbating cohort.

Abbreviation: COPD, chronic obstructive pulmonary disease.

Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy

Table 1 Characteristics of Patient Cohorts and Subgroups in the Year Prior to the Index Date

Table 2 HCRU Events and Mortality During the Outcome Year

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy

Figures & data

Table 1 Characteristics of Patient Cohorts and Subgroups in the Year Prior to the Index Date

Table 2 HCRU Events and Mortality During the Outcome Year

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date